A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

NCT07739589 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Residual Drug Amount of EE and LNG

Interventions

DRUG: Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System

Sponsor

Insud Pharma

Collaborators

[object Object]
[object Object]